Connect with us

Spread & Containment

7 “Perfect 10” Stocks to Buy Now

7 "Perfect 10" Stocks to Buy Now



In a financial environment riddled with unprecendented levels of uncertainty, investors are at wits’ end. When it comes to finding an investment strategy that will yield returns, traditional methods might not be as dependable. So, how should investors get out of the rut?  

In times like these, a more comprehensive stock analysis can steer investors in the direction of returns. Rather than looking solely at more conventional factors like fundamental or technical analyses, other metrics can play a key role in determining whether or not a particular stock is on a clear path forward.  

TipRanks offers a tool that does exactly that. Its Smart Score measures eight key metrics including fundamentals and technicals while also taking into account analyst, blogger and news sentiment as well as hedge fund and corporate insider activity. After analyzing each metric, a single numerical score is generated, with 10 being the best possible result. 

Using the Best Stocks to Buy tool, we were able to pour through TipRanks’ database, filtering the results to show only the names that have earned a “Perfect 10” Smart Score. We found seven that managed to tick all of the boxes. Let’s jump right in. 

Limelight Networks, Inc. (LLNW) 

Limelight Networks is best known for being a content delivery network (CDN) service provider, with its solutions enabling organizations to deliver digital assets that are fast, reliable and secure. With the growth story set to get even better, it’s no wonder LLNW has scored fans out on the Street. 

Among the bulls is Northland Capital analyst Michael Latimore. After hosting a call with the company’s management team, he told clients that he walked away even more positive on the stock. “LLNW is a company with improving growth rates, expanding margins, and top tier customers; and getting a little help via work-from-home. We believe management remains confident in growth patterns, especially given new customers coming on board, and a healthy additional tailwind via work-from-home,” the analyst commented.  

To support his bullish thesis, Latimore highlights the fact that going forward into Q2 and Q3, new customer launches should drive significant sequential growth, more so in full year 2021 than full year 2020. Online gaming updates as well as new sports content could also help propel the stock forward. 

Latimore added, “Traffic related to work-from-home peaked at the end of March, but LLNW is managing more traffic than ever on a daily basis... LLNW has perfected its platform for OTT video and is in every conversation among new meaningful OTT video and live event providers.” 

As its top 20 customers, which account for 77% of revenue, are financially sound, the deal is sealed for Latimore. To this end, the five-star analyst left an Outperform rating and $8 price target on LLNW, implying 51% upside potential. (To watch Latimore’s track record, click here)

Do other analysts agree with Latimore? As it turns out, they do. With 100% Street support, or 4 Buy ratings to be exact, the message is clear: LLNW is a Strong Buy. At $7.50, the average price target is less aggressive than Latimore’s, but still suggests 41% upside potential. See the LLNW stock analysis

Krystal Biotech, Inc. (KRYS) 

Using its STAR-D platform, Krystal Biotech develops and commercializes innovative therapies that target various dermatologic conditions. On the heels of its recent data release, some Wall Street pros believe that now is the time to snap up shares. 

During the American Society of Gene & Cell Therapy (ASGCT) virtual meeting, the company presented positive in vitro preclinical data for replication-defective HSV-1-based gene therapy (GT), KB407, in cystic fibrosis (CF), the most common inherited genetic disorder in the U.S. Based on the update, the asset was able to infect small airway epithelial cells (SAECs) and generate a robust expression of functional, full-length human CFTR protein that properly traffics to the cell membrane.  

Commenting on this result for Chardon Capital, five-star analyst Gbola Amusa stated, “This result suggests KB407 has overcome the issues of limited-capacity GT vectors not infecting the appropriate cells of the lungs.” He also pointed out that KB407 went head-to-head with Orkambi (G418) in relevant mutations, but also worked broadly on functional correction of the cystic phenotype of organoids. 

Amusa added, “We thus see the KB407 in vitro data as a good start en route to Krystal testing KB407 for other issues that have held back GTs for CF, namely: (1) redosing (B-VEC data suggest Krystal's vectors can be re-dosed), and (2) delivery (upcoming mouse nebulizer data will shed light).” 

It should be noted that Vertex Pharmaceuticals is already well positioned within the space, but Amusa argues that a therapy for the 10% of CF patients with class I mutations, which cause the most severe phenotypes, still isn’t available, leaving the door wide open for KRYS. 

Based on all of the above, Amusa calls the stock a Top Pick for 2020. Along with a Buy rating, the $100 price target remains unchanged. This target puts the upside potential at 89%. (To watch Amusa’s track record, click here)      

What does the rest of the Street think about Krystal Biotech’s long-term growth prospects? It turns out that other analysts also have high hopes. Only Buy ratings, 6, in fact, have been received in the last three months, so the consensus rating is a Strong Buy. In addition, the $81 average price target indicates 53% upside potential. See the KRYS stock analysis

Celsius Holdings, Inc. (CELH) 

Celsius Holdings offers a portfolio of fitness drinks under the flagship CELSIUS brand that provide healthy energy while accelerating the metabolism and burning body fat. Following its Q1 2020 earnings release, the analyst community is singing its praises. 

On May 12, CELH reported revenue of $28.2 million, which flew past the Street’s $13.4 million call and reflected a whopping 94.6% year-over-year gain. Up 660 basis points year-over-year, gross margin also surpassed the consensus estimate.  

The driver of this impressive quarterly performance? Maxim Group’s Anthony Vendetti believes it was “the continued momentum and traction CELH is gaining as its products expand both nationally and abroad.” Even though he acknowledges that consumer purchasing behaviors have changed, the analyst highlights the fact that functional beverage demand is holding up strong. 

In addition, COVID-19 played a role during the first quarter. “CELH has seen a surge in grocery deliveries and online orders and, in response, has stockpiled inventory and secured additional distribution and co-packer agreements. Additionally, the company has pivoted its marketing resources to digital programs, better reflecting the current macro environment. Although we believe that CELH has received a short-term sales bump from COVID-19, we remain positive in the long-term as the company continues to expand its distribution network and highlight itself as a 'lifestyle brand,' where active, routine customers continue to drive growth,” Vendetti explained. 

All of the above combined with a compelling valuation prompted Vendetti to maintain a Buy recommendation. On top of this, the four-star analyst bumped up the price target from $8 to $12, bringing the upside potential to 33%. (To watch Vendetti’s track record, click here)     

Looking at the consensus breakdown, 4 Buys and no Holds or Sells give CELH a unanimous Strong Buy analyst consensus. Not to mention the $11.31 average price target suggests 26% upside potential. See the CELH stock analysis

NeoPhotonics Corporation (NPTN) 

NeoPhotonics is one of the top manufacturers of ultra-pure light lasers and optoelectronic products that transmit, receive and switch the highest speed over distance digital optical signals for cloud and hyper-scale data center internet content provider and telecom networks. After tuning in to the company’s recent webinar, one analyst thinks its future is bright. 

Needham’s Alex Henderson cites a few key takeaways from the webinar discussing “Optical Technology Trends and Capacity in IP over DWDM”. “The primary points of the presentation is the shift to higher speeds and the emergence of standardization enabling Pluggables strengthens Neo's competitive position should drive increased market share and improve margins,” he commented. 

Part of what makes NPTN a stand-out, in Henderson’s opinion, is that it has a diverse product lineup that’s ready to accelerate in new arenas. It has also already been seeing traction with its more advanced capabilities. This translates to a significant competitive advantage for NPTN. Additionally, the company believes that its speeds will reach 400G and above, which will give it the chance to capture even more market share.  

On top of this, the expansion into the C++ extended spectrum bands is producing design wins. Henderson explained, “Neo's ability to use the same components and to take advantages of the ultra-clean signal enables Neo to offer as much as a 50% increase in spectral capacity using C++. This is an important advantage. Neo is already seeing considerable traction particularly in China for this technology.”  

Taking all of this into consideration, Henderson stayed with the bulls. Along with a Buy rating, he reiterated a $12 price target. This target conveys the five-star analyst’s confidence in NPTN’s ability to surge 45% in the next twelve months. (To watch Henderson’s track record, click here)     

In general, other analysts echo Hendersons’s sentiment. 7 Buys and 1 Hold add up to a Strong Buy consensus rating. A twelve-month rise of 45% could be in store if the $12.07 average price target is met. See the NPTN stock analysis

Bunge Limited (BG

Counting itself as the world’s largest soybean processor, Bunge Limited operates as an agribusiness and food company. Connecting farmers and consumers, the company is also involved in food processing, grain trading and fertilizer. Sure, 2020 has not been kind to this stock, with shares down 38% year-to-date, but several analysts see a turnaround on the horizon. 

The recent negative sentiment surrounding BG can be attributed to its most recent quarterly performance. Looking at revenue, the figure came in at $9.2 billion, missing the consensus estimate by 8.6%. It also didn’t help that a loss of $1.46 per share was reported.  

That being said, Baird analyst Ben Kallo is looking at the glass half full. Speaking to its recent portfolio optimization, the five-star analyst believes the company has “unlocked substantial value.” Additionally, the stock is trading at levels that are less than book value. As a result, he argues that now is the time for investors to “get more constructive on the longer-term earnings power story, enabled by BG's leading (and underappreciated) asset footprint.” 

It should also be noted that last week, BG declared a regular quarterly cash dividend of $0.50 per common share as well as a $1.22 per share quarterly dividend on its 4.9% cumulative convertible perpetual preference shares.  

With everything that Bunge has going for it, it’s clear why Kallo is optimistic. Giving the stock a thumbs up, the analyst upgraded his rating from Neutral to Outperform. At $46, his price target suggests shares could climb 30% higher in the twelve months ahead. (To watch Kallo’s track record, click here)      

Turning now to the rest of the Street, most other analysts are on the same page. Out of 4 analysts that have thrown an opinion into the mix, 3 were bullish, making the consensus rating a Strong Buy. To top it all off, the $57.50 average price target speeds past Kallo’s and brings the upside potential to 63%. See the BG stock analysis

PetIQ, Inc. (PETQ) 

Through retail channels across the U.S., PetIQ offers affordable pet health and wellness products as well as veterinary services. While the company, like the broader market, has been impacted by the COVID-19 pandemic, some analysts believe gains are in store post-virus. 

Writing for Oppenheimer, five-star analyst Brian Nagel tells clients that PETQ is well-positioned to stage a post-COVID-19 rebound. “We are increasingly optimistic that the products and services businesses of PETQ should prove situated well to capitalize upon improved underlying consumer demand, given a recent surge in pet adoptions and rescues amid broad-based shelter in place orders across the U.S.,” he said. 

Adding to the good news, PETQ just unveiled its telehealth platform. As part of the collaboration with whiskerDocs, prior PetIQ service customers will have access to various telehealth services, with a more comprehensive digital experience for new and existing customers coming later down the road. 

To conclude, Nagel opined, “In our view, PETQ represents one of the most compelling, early stage small-cap growth stories to emerge in the consumer sector in a long while. A few key factors underpin our initial positive stance on the shares: 1) Potential for sustained, outsized topline expansion, owing to a still small market share, a unique consumer proposition, and favorable industry dynamics; 2) Already compelling free cash flow generation and the opportunity for rapidly expanding sales to leverage largely fixed operating expenses; and 3) An attractive valuation.” 

It should come as no surprise, then, that Nagel kept an Outperform call and $50 price target on the stock. Given this target, shares could jump 73% in the next year. (To watch Nagel’s track record, click here)      

Like Nagel, other analysts also like what they’re seeing. With 3 Buys and no Holds or Sells, the word on the Street is that the stock is a Strong Buy. In addition, the $39 average price target implies 35% upside potential. See the PETQ stock analysis

Ocular Therapeutix, Inc. (OCUL) 

Last but not least on our list of Perfect 10s we have Ocular Therapeutix, which leverages its formulation expertise to develop cutting-edge treatments. With the company dosing the first patient in the Phase 1 open-label trial of OTX-CSI, its bioresorbable insert designed to release drug to the ocular surface for up to three months as a treatment of dry eye disease (DED), it’s clear why Wall Street focus has locked in on this healthcare name.  

Looking more closely at the trial, it’s being conducted in a single center in the U.S., with it slated to enroll five patients and follow them for four months. As for why OCUL is garnering so much attention, it comes down to the design of the therapy. 

OTX-CSI enables preservative-free delivery of a constant dose of cyclosporine, which could be less irritating than eye drop formulations. In addition, blocking the punctum may provide immediate relief for dry eye symptoms.  

H.C. Wainwright analyst Yi Chen acknowledges that there’s already a treatment available for DED called RESTASIS, which generated sales of $1.1 billion in 2019. However, the analyst points out that the irritating side effects and slow onset of efficacy have led to high patient dropout rates.  

Expounding on this, Chen stated, “In our view, an intracanalicular insert approach could be a better route of administration for chronic DED treatment; OTX-CSI could be less irritating and faster-acting compared to RESTASIS, in addition to eliminating the burden of twice-daily eye drop instillation required for RESTASIS.”  

It should be noted that OCUL also faces competition from Oyester Point Pharma and its OC-01 candidate, but its recent data readout revealed lackluster levels of efficacy. “OC-01’s efficacy on DED symptom is a mixed bag at best, in our view, and neither dose met the symptom endpoint twice in the two studies. In addition, neither dose met the secondary symptom endpoint,” Chen mentioned. 

All in all, Chen believes OCUL’s long-term growth prospects are strong. As a result, the five-star analyst reiterated a Buy rating and $10 price target, suggesting 39% upside potential. (To watch Chen’s track record, click here

When it comes to other analysts, they take a similar approach. Two other analysts have published a review in the last three months, and both rated the stock a Buy, so the consensus rating is a Strong Buy. Based on the $9.67 average price target, the upside potential lands at 34%. See the OCUL stock analysis

The post 7 "Perfect 10" Stocks to Buy Now appeared first on TipRanks Financial Blog.

Read More

Continue Reading


Watch: Biden Tells People To Stop Questioning COVID Shots

Watch: Biden Tells People To Stop Questioning COVID Shots

Authored by Steve Watson via Summit News,

In remarks made Wednesday, Joe Biden…



Watch: Biden Tells People To Stop Questioning COVID Shots

Authored by Steve Watson via Summit News,

In remarks made Wednesday, Joe Biden argued that people, including potential “leaders” should stop saying “inflammatory things” about COVID vaccinations and fall into line with what his administration is telling them to do.

“What leaders say matter, in terms of people’s confidence in things they’re not sure about,” biden began.

He continued, “And one of those areas — you saw what happened with regard to the crisis — health crisis that we had that cost us — we lost well over a million people. And as time began to move on, you had more and more voices saying, “No, no, no. You don’t need to get that shot. You don’t need to be — get — you don’t need to.”

“We have a new strain of COVID now, and we have answers for it,” Biden contended, further stating “I just would urge those in public life and both political parties or no political party to be cautious about the ac- — the sometimes inflammatory things you say about this, because people’s lives are at stake.”


That will be the COVID shots that don’t prevent anyone from getting COVID or stop transmission of the virus then will it? The ones that cause more serious side effects in children than they do save lives?

The comments come in the wake of revelations that Anthony Fauci was secretly escorted into CIA and State Department meetings to steer the direction of the COVID origins investigation away from the lab leak evidence.

*  *  *

Brand new merch now available! Get it at

In the age of mass Silicon Valley censorship It is crucial that we stay in touch. We need you to sign up for our free newsletter here. Support my sponsor – Summit Vitamins – super charge your health and well being.

Also, we urgently need your financial support here.

Tyler Durden Thu, 09/28/2023 - 17:00

Read More

Continue Reading


Dollar cost averaging: navigating market volatility for long term success

Back in March 2022, Toby Roberts advocated for a dollar cost averaging approach to investing. Considering that The Montgomery Small Companies Fund has…



Back in March 2022, Toby Roberts advocated for a dollar cost averaging approach to investing. Considering that The Montgomery Small Companies Fund has returned 11.19 per cent in the three months to 31 August, resulting in an outperformance of 8.97 per cent over its benchmark, I wanted to explore whether dollar cost averaging has provided another win for investors.

Back in March last year Toby wrote; “It is periods of uncertainty like this when investors may like to be reminded of the merits of dollar cost averaging. Dollar cost averaging is the investing strategy [equally] dividing up the total amount to be invested and periodically purchasing stocks, in an effort to reduce the impact of volatility and emotion on an investment. This is an investment strategy all Australian employees will be familiar with as it reflects the periodic contributions employers make into their superannuation.”

Importantly, a large lump sum invested at the beginning of a bull run in markets is always going to beat a dollar-cost-averaging approach, in which the investor holds a lot more cash until the amount earmarked has been fully invested. But during periods of volatility or major market declines, dollar cost averaging helps to ease the pain of falls while ensuring more units (of individual stocks or units in a managed fund) are purchased at cheaper prices as those prices get cheaper.

The Global Financial Crisis and the more recent COVID-19 pandemic were classic examples of events that inspired individuals to act in concert, producing the consequences of herd behaviour and panic. 

Thanks to the indefatigable and unchanging nature of human behaviour, such events are reasonably frequent – indeed, they should be expected. Tey inspire fear and apprehension, which is why the dollar cost averaging approach is a good method to consider. Dollar cost averaging takes the emotion out of investing and helps to ensure sensible decisions are made while also providing some comfort when the tide goes out. And keep in mind bear markets are transitory.

Rather than be frightened of the inevitable volatility, the dollar cost averaging strategy will see you excited by periods of panic and looking forward to the cheaper prices that ensue. 

For the U.S. S&P500, 2022 produced the seventh-worst calendar year return since 1928. But last year’s awful performance was a great thing for anyone who was putting money into the market on a periodic basis because bear markets are great for dollar cost averaging.

Before we examine the benefits of applying the dollar cost averaging approach suggested by Toby from March last year, lets revisit what the strategy is.

Dollar cost averaging, which can be applied to individual securities or stocks, index funds, and actively managed funds – the latter being my preference for young investors who have a great deal of time and very long runways for growth but no time to research investing in stocks directly.

Following an explanation of dollar cost averaging, we will explore a version I developed many years ago and first revealed to Ross Greenwood’s listeners when he hosted the 2GB Radio Money News program.

There are two ways to approach the stock market. The first, which is extremely popular, is betting on the ups and downs, to treat stocks like a gambler betting on black or red at the roulette wheel.  The problem with this approach is that the stock market becomes a casino, and the house usually wins.

The alternative is to recognize stocks are pieces of businesses.  Businesses create wealth by becoming more valuable because they generate growing profits, which can be distributed – even though they may not be.

Build value, ignore price

The process of a business creating wealth is a simple one, in theory. It’s much harder on the ground of course, requiring skill, intestinal fortitude, experience, teamwork, and a healthy dose of good fortune.

A company starts with some capital that has been contributed by its shareholders. If the venture is successful, the investment will generate revenues in excess of expenses, and a profit will accrue. This profit can then be distributed but may instead be reinvested, which builds on the original equity contributed and, therefore, the value of the enterprise. 

Think about it this way; a bank account is opened with $100,000 and earns a 20 per cent return from the interest in its first year. Now you must agree that would be a very special and valuable bank account. In fact, given that interest rates on term deposits, at the time of writing, are about four per cent, you could sell the special bank at an auction and someone would bid a lot more than the $120,000 it now has deposited after the first year. 

I wouldn’t be surprised if someone paid four or five times the balance of the bank account to own it. If they thought there was going to be a recession, or they thought interest rates might fall again, they’d be falling over themselves to own that special bank account for perhaps $500,000.

And if the bank account continued to earn 20 per cent annually for thirty years and the owner reinvested that interest, that bank account would have an equity balance of over $27 million and still be earning 20 per cent. Auction a $27 million bank account earning 20 per cent per annum and you can expect to see bids of more than $100 million (subject to interest rates at the time).

Can you see what I’ve done? I’ve just explained how businesses build wealth and how the stock market (the auction house) prices them.

The second approach to the stock market is to buy shares in those businesses that are able to sustainably generate high returns on their equity, and to wait for the wealth creation process to do its thing. 

Of course, while you are letting the years pass and while the business performs its wealth-creation miracle, the auction house will be open. On some days, the attendees will be jovial and full of optimism, paying insanely high prices for the ‘bank accounts’ being auctioned. At other times they will be depressed and despondent, only thinking the worst. 

Their moods however have nothing to do with the quality of that bank account that continues to earn 20 per cent per annum.  Their mood is instead influenced by exogenous factors such as whether Donald Trump will be re-elected, or whether China’s unemployment rate is rising or falling. These things affect the ‘price’ of the bank accounts being auctioned but they have nothing to do with their ‘value’ or worth.

Dollar Cost Averaging

The dollar cost averaging strategy is what I call a ‘contrarian’ strategy. It forces you to be less optimistic when others are very optimistic while ensuring you are more optimistic when others are despondent.

The idea is to be greedy when others are fearful and fearful when others are greedy, to quote one of the world’s most famous and successful investors.

On days when the stock market falls because everyone at the auction house is frightened, you simply need to remind yourself of the long-term wealth creation process of business, and apply dollar cost averaging.

We begin by setting ourselves the goal of investing a fixed amount of money – say $1,000 – every month or every quarter in either a particular stock, a portfolio of stocks, an index fund, or an actively managed fund. No matter what the market throws at us, no matter how crazy the auction house becomes, we simply keep investing our $1,000 monthly or quarterly – whatever was decided.

If the unit price of the actively managed fund is $2.50, the $1,000 investment will buy 400 units. If the unit price falls to $2.00, the next $1,000 investment will buy 500 units. And when sentiment in the auction house is overly optimistic and the unit price is $5.00, the $1,000 investment will buy only 200 units. With dollar cost averaging, more units are acquired at cheaper prices than at expensive prices but the strategy is always acquiring more units.

One benefit of the strategy is it helps the investor avoid being paralysed by fear. This can happen if an initial investment is made at $5.00 and then the unit price falls to $2.50. Many investors listen to the noise surrounding the events that caused the price drop rather than taking advantage of it. Instead of adding to their investment, they forget the long-term wealth creation process of business growth and run for the hills. The stock market is one of the few markets where shoppers zip up their wallets and run for the hills when the items are ‘On Sale’.

Some investors who buy at $5.00, panic when the price falls to $2.50. Being unable to bear the losses anymore, and fearing even greater losses, they sell at $2.50. When the market eventually recovers – it usually does – they miss out on the recovery. Other investors who buy at $5.00 are also petrified but do nothing when the price falls to $2.50. They simply wait until the prices recover.  The problem with this strategy is that they have lost through the time value of money and they’ve not taken advantage of the opportunity to generate a profit from the recovery.

Dollar cost averaging seeks to mitigate the opportunity cost associated with doing nothing.

Let’s look at a ten-month period during which one thousand dollars is invested in a fund monthly, and the unit price of that fund falls from $10.00 to $4.00 and then rises back to $10.00.

Table 1.  Dollar-Cost Averaging example.

Dollar Cost Averaging Example

If all $10,000 was invested at the beginning of the period, the value at the end of the period would be $10,000. And if all the funds ($10,000) were invested at the end of the period, the value would again be $10,000.

Because the investor took advantage of the auction house’s depressed sentiment during the period using the dollar cost averaging strategy, additional units were purchased while the units were at low prices. The $10,000 invested is worth over $17,000 at the end of the period because the average purchase price was $5.88 per unit and the units ended the period at $10.00.

Of course, it’s not always peaches and cream. If the unit prices had risen first and then fallen back to the starting price, the investor would have less value than investing the funds all at the beginning or at the end because they purchased additional units at higher prices.

But the end of the 10-month period doesn’t represent the end of the experience. As we demonstrated earlier, the process of business wealth creation takes years. Ten months is too short a time frame to consider the strategy a success or otherwise. 

Provided the investor has picked a portfolio of select quality companies whose earnings march upwards over the years, or a fund manager that invests with discipline in such companies, the long-term value of the shares or units will rise, and so will the portfolio’s value.

Applying it to the real world

Figure 1.  Performance of The Montgomery Small Companies Fund

Performance of the Montgomery Small Companies FundSource: Fundhost

I examined the outcome of investing $10,000 each quarter, since inception, in the Montgomery Small Companies Fund (the Fund) with the objective of comparing it to an initial investment of the same total amount as that which was invested through dollar cost averaging.

It’s an unfair comparison because the unit mid-price of the Fund at the time of writing is $1.223 versus the unit price at inception of $1.00. Moreover, the unit price has not spent a great deal of time below the $1.00 unit price at inception, which means there haven’t been a huge number of opportunities to acquire more units at prices below the inception price.

I have also ignored distributions. They are neither included in returns nor reinvested. The returns from investing all at inception or via a dollar cost averaging strategy would be even better than those described here.

Nevertheless, it remains an instructive exercise, especially for those who might be more nervous about investing and those who might fear the effects of recessions, war, inflation, and other exogenous factors on the performance of the stock market.

Keep in mind the period begins on 20 September 2019. The Fund was launched just a few months before COVID-19 hit. If you were ever going to have to endure an event that justified your fears about investing at the wrong time, it would be COVID-19. 

Table 2.  Dollar Cost Averaging $10,000 into the Montgomery Small Companies Fund quarterly.

Dollar Cost Averaging $10,000 into the Montgomery Small Companies Fund quarterly.

Given there were only two quarterly investment dates from 16 where the unit price was below the initial unit price at inception and that the unit price at the end of the period is higher than at the beginning, it is a reasonable assumption that investing all at the beginning will produce a better outcome than dollar cost averaging. Gary and Dom are doing too good a job managing the Fund for dollar cost averaging to be superior.

And that is evident in the results. Investing $10,000 each quarter resulted in an investment of $160,000 and the acquisition of 141,474.6 units for an average price of $1.13, clearly higher than the initial price of $1.00. 

Had you invested $160,000 at the inception price of $1.00, the value today would be $195,696. The dollar cost averaging strategy resulted in $160,000 invested, which at the 20 September 2023 unit price of $1.2231, is now worth $173,037.

As I mentioned, it is an unfair comparison. And hindsight plays a big part. Because I am assessing the strategies today, I am comparing 16 investments of $10,000 with the same total amount at inception. I couldn’t have known at inception that investing $160,000 would be the appropriate amount to invest. I might have invested much less or much more. 

The exercise, however, does demonstrate that a dollar-cost averaging strategy can ensure disciplined habits while also securing attractive long-term returns (provided the manager continues to do a good job) even if serious market setbacks have to be endured. 

Obviously, it’s easy to look back at these things after the market has come roaring back.

Indeed, it is the ever-present possibility of market setbacks that renders the dollar cost averaging approach a comfortable strategy for navigating those adverse episodes in markets. Dollar cost averaging ensures more units are purchased as the market or the fund declines and aids a more rapid recovery as markets return to confidence. Down markets are a wonderful time to be long-term bullish.

Of course, if you have justifiable confidence in the manager’s ability to create wealth over the long term, then maximising an investment initially is the way to go. The caveat is that we just don’t know what could happen in between. 

Portfolio Performance is calculated after fees and costs, including the investment management fee and performance fee, but excludes the buy/sell spread. All returns are on a pre-tax basis. This report was prepared by Montgomery Lucent Investment Management Pty Limited, (ABN 58 635 052 176, Authorised Representative No. 001277163) (Montgomery) the investment manager of the Montgomery Small Companies Fund. The responsible entity of the Fund is Fundhost Limited (ABN 69 092 517 087) (AFSL No: 233 045) (Fundhost). This document has been prepared for the purpose of providing general information, without taking account your particular objectives, financial circumstances or needs. You should obtain and consider a copy of the Product Disclosure Statement (PDS) relating to the Fund before making a decision to invest. The PDS and Target Market Determination (TMD) are available here: While the information in this document has been prepared with all reasonable care, neither Fundhost nor Montgomery makes any representation or warranty as to the accuracy or completeness of any statement in this document including any forecasts. Neither Fundhost nor Montgomery guarantees the performance of the Fund or the repayment of any investor’s capital. To the extent permitted by law, neither Fundhost nor Montgomery, including their employees, consultants, advisers, officers or authorised representatives, are liable for any loss or damage arising as a result of reliance placed on the contents of this document. Past performance is not indicative of future performance.

Read More

Continue Reading

Spread & Containment

Wearable patch wirelessly monitors estrogen in sweat

The sex hormone commonly known as estrogen plays an important role in multiple aspects of women’s health and fertility. High levels of estrogen in the…



The sex hormone commonly known as estrogen plays an important role in multiple aspects of women’s health and fertility. High levels of estrogen in the body are associated with breast and ovarian cancers, while low levels of estradiol can result in osteoporosis, heart disease, and even depression. (Estrogen is a class of hormones that includes estradiol as the most potent form). Estradiol is also necessary for the development of secondary sexual characteristics in women and regulates the reproductive cycle.

Credit: Caltech

The sex hormone commonly known as estrogen plays an important role in multiple aspects of women’s health and fertility. High levels of estrogen in the body are associated with breast and ovarian cancers, while low levels of estradiol can result in osteoporosis, heart disease, and even depression. (Estrogen is a class of hormones that includes estradiol as the most potent form). Estradiol is also necessary for the development of secondary sexual characteristics in women and regulates the reproductive cycle.

Because of its many functions, the hormone estradiol is often specifically monitored by physicians as part of women’s health care, but this usually requires the patient to visit a clinic to have blood drawn for analysis in a lab. Even at-home testing kits require samples of blood or urine to be mailed to a lab.

But now Caltech researchers have developed a wearable sensor that monitors estradiol by detecting its presence in sweat. The researchers say the sensor may one day make it easier for women to monitor their estradiol levels at home and in real time.

The research was conducted in the lab of Wei Gao, assistant professor of medical engineering, investigator with the Heritage Medical Research Institute, and Ronald and JoAnne Willens Scholar. In recent years, Gao has developed sweat sensors that detect cortisol, a hormone associated with stress; the presence of the COVID-19 virus; a biomarker indicating inflammation in the body; and a whole slew of other nutrients and biological compounds.

Gao says the development of the estradiol sensor was spurred in part by requests from people who were unsatisfied with the options they had for monitoring their estrogen levels and had seen his previous work.

“People often ask me if I could make the same kind of sweat sensor for female hormones, because we know how much those hormones impact women’s health,” Gao says.

One population of women who would benefit from estradiol monitoring are those who are attempting to conceive a child, either naturally or through in vitro fertilization. The success of either method is dependent on getting timing right with regards to ovulation, but not all women have a reproductive cycle that follows a regular schedule. Some women have been able to track their ovulation by monitoring their body temperature, but Gao says that method has limited usefulness because it’s not very accurate and body temperature doesn’t increase until ovulation has begun.

“But estrogen increases before ovulation,” he says. “With this sweat sensor, we would be able to give people notice ahead of time.”

Other individuals who could benefit from a wearable estrogen sensor are those undergoing hormone replacement therapy (HRT) because their bodies do not produce sufficient estradiol. In these patients, estradiol levels need to be carefully monitored to ensure they are taking the correct dosage.

The sensor Gao’s team developed is similar in many ways to the various sensors developed by the group in the past. It is built on a flexible plastic membrane; has tiny etched passages (microfluidics) for channeling small amounts of sweat into the sensor; and inkjet-printed gold nanoparticles and titanium carbide films (known as MXenes) that give the sensor a largesurface area and electrical conductivity to increase its sensitivity.

The primary challenge, and what dictated changes in the sensor’s design this time around, is that estradiol, which already is present at fairly low levels in the blood, is roughly 50 times less concentrated in sweat.

“Since it’s such a low concentration, it’s very challenging to detect estradiol automatically in sweat,” Gao says.

For the new sensor, the research team made use of short single-stranded DNA known as aptamers. Aptamers work as artificial antibodies and are designed to bind specifically to a target molecule. The aptamers are attached to a surface modified with gold nanoparticles and bind to single-stranded DNA molecules tagged with a molecule that can directly donate or accept electrons under certain conditions. When an aptamer binds to an estradiol molecule, it releases the redox molecule. That molecule is recaptured by a nearby electrode made of MXene-coated gold nanoparticles, generating an electrical signal that correlates with the estradiol level. That hardware then wirelessly transmits the data it collects to an app that runs on a smart phone, providing a simple interface for the user.

Another innovation in this device was the design of the microfluidics that collect sweat and channel it into the sensor. Tiny automatic valves incorporated in the microfluidics allow only a small, fixed amount of sweat into the sensor and then prevent additional sweat from entering. The design enables stable estradiol analysis without additional sweat disturbing the process. Moreover, to account for difference in sweat composition, the device also collects information about sweat pH, sweat salt levels, and skin temperature, and uses them for real-time calibration.

Testing in the laboratory has shown that the sensor can reliably and accurately track the changing levels of estradiol in sweat over the course of the reproductive cycle, from the lowest level during menstruation to its highest level (10 times greater) during ovulation.

Gao says he plans to continue working on this technology to allow it to monitor other female hormones, like luteinizing hormone or progesterone, which are both involved in ovulation. He also hopes to miniaturize all these sensors so they could all fit inside of a small wearable device such as an inconspicuous ring that can be worn on the finger.

The paper describing the research, “A wearable aptamer nanobiosensor for non-invasive female hormone monitoring,” appears in the Sept 28 issue of Nature Nanotechnology. Co-authors are postdoctoral scholar research associates in medical engineering Cui Ye, Minqiang Wang, and Juliane R. Sempionatto; medical engineering graduate students Jihong Min (MS ’19), Heather Lukas (MS ’21), Jiahong Li (MS ’23), and Changhao Xu (MS ’20); and Roland Yingjie Tay, formerly of Caltech and now with Nanyang Technological University of Singapore.

Funding for the research was provided by the National Institutes of Health, the National Science Foundation, the Office of Naval Research, an American Cancer Society Research Scholar Grant, and a Sloan Research Fellowship.

Read More

Continue Reading